Cargando…

Analysis of pramipexole dose–response relationships in Parkinson’s disease

BACKGROUND: Pramipexole (PPX), a non-ergot dopamine receptor agonist, is a first-line treatment for Parkinson’s disease (PD). A critical dose level above which a better benefit-to-harm ratio exists has not been examined. METHODS: Chinese PD patients (n=464) were retrospectively analyzed by PPX maint...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ying, Sun, Sheng-Gang, Zhu, Sui-Qiang, Liu, Chun-Feng, Liu, Yi-Ming, Di, Qing, Shang, Hui-Fang, Ren, Yan, Xiang, Wei, Chen, Sheng-Di
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207331/ https://www.ncbi.nlm.nih.gov/pubmed/28096656 http://dx.doi.org/10.2147/DDDT.S112723

Ejemplares similares

Update on the use of pramipexole in the treatment of Parkinson’s disease
por: Constantinescu, Radu
Publicado: (2008)

Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease
por: Piedad, John C. P., et al.
Publicado: (2012)

The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study
por: Wang, Ying, et al.
Publicado: (2014)

Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)

Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease
por: Sun, Yongqi, et al.
Publicado: (2022)

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
por: Faddoul, Lama, et al.
Publicado: (2018)

Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease
por: Kano, Osamu, et al.
Publicado: (2008)

Retracted: Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease
por: Dong, An-qi, et al.
Publicado: (2022)

Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations
por: Xiang, Wei, et al.
Publicado: (2018)

Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels
por: Huang, Jinzhong, et al.
Publicado: (2020)

Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease
por: Eisenreich, Wolfram, et al.
Publicado: (2010)

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Possible effects of pramipexole on neck muscles in a patient with Parkinson's disease
por: Filippi, Roberto, et al.
Publicado: (2014)

Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patients
por: Luo, He-Ting, et al.
Publicado: (2016)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease
por: Hametner, Eva-Maria, et al.
Publicado: (2012)

Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole
por: Salawu, Fatai Kunle
Publicado: (2012)

Pramipexole-induced antecollis in patients with Parkinson's disease: Two cases and literature review
por: Iijima, Mutsumi, et al.
Publicado: (2015)

Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome
por: Han, Steve C., et al.
Publicado: (2020)

Efficacy of pramipexole on quality of life in patients with Parkinson’s disease: a systematic review and meta-analysis
por: Li, Tao, et al.
Publicado: (2022)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Pramipexole use and the risk of pneumonia
por: Ernst, Pierre, et al.
Publicado: (2012)

Pramipexole: new use for an old drug – the potential use of pramipexole in the treatment of restless legs syndrome
por: Benbir, Gulcin, et al.
Publicado: (2006)

Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D(3 )receptor
por: Joyce, Jeffrey N, et al.
Publicado: (2004)

3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
por: Windolf, Hellen, et al.
Publicado: (2022)

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
por: Antonini, Angelo, et al.
Publicado: (2011)

Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
por: Choi, Yoonjae, et al.
Publicado: (2010)

Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
por: Choi, Yoonjae, et al.
Publicado: (2011)

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
por: Schapira, Anthony HV, et al.
Publicado: (2013)

Auditory Musical Hallucinations Associated With Extended-Release Pramipexole in an Elderly Patient With Parkinson's Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2014)

Dramatic Responses to Low-Dose Pramipexole in Painful Legs and Moving Toes Syndrome
por: Umezawa, Gakusuke, et al.
Publicado: (2023)

Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study
por: Zhou, Haiyan, et al.
Publicado: (2021)

Burning mouth syndrome responsive to pramipexol
por: Stuginski-Barbosa, J., et al.
Publicado: (2008)

Automatic behavior and communication due to pramipexole
por: Walker, Ruth H.
Publicado: (2016)

Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
por: Hauser, Robert A., et al.
Publicado: (2014)

Retraction: Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
Publicado: (2015)

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
por: Hauser, R A, et al.
Publicado: (2014)

Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients
por: Deutschländer, Angela, et al.
Publicado: (2016)

Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: A randomized parallel-group trial
por: Ziaei, Ehsan, et al.
Publicado: (2022)

The use of pramipexole in drug-induced parkinsonism: A case study on a patient with bipolar depression
por: Bueno Sanya, L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kvdb9e7ql05ffv19093cbv1l3p